FDA 483 - CoreRX Inc. - March 06, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of CoreRX Inc., a contract manufacturer of prescription drugs in Clearwater, FL, revealed significant deficiencies in their quality systems, equipment qualification, and cleaning procedures. The firm failed to adequately investigate out-of-specification results, ensure equipment was properly designed and qualified, and establish sufficient procedures to prevent objectionable microorganisms. One critical observation regarding inadequate investigations was a repeat from a previous inspection.
ID · c5d7672d-dfb4-4e43-ac1d-b08c5c9efdb1